Wellling’s and Motinova’s New E-bike Motor Series Debut at EUROBIKE 2022
14.7.2022 05:14:00 EEST | Business Wire | Press release
Motinova’s and Welling’s latest E-bike motor series debut at EUROBIKE 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005981/en/
New Motinova and Welling E-bike motor series offerings at Booth H8-I20, EUROBIKE 2022 (Indoors) (Photo: Business Wire)
By 2030, the global E-Bike market will reach 19 million units. As the green and low-carbon lifestyle trends, E-bikes have gradually become an alternative choice for urban commuters and field riders. Welling and Motinova offer three central motors for large chain wheels: Welling W6000, Welling 8500, and Motinova MT6000, featuring higher power density, higher efficiency, shorter response time, and lower wastage rate.
Welling W6000 for urban E-bikes: This high-performing central motor for large chain wheels is compact and low-noise designed (under 52dB), enabling a quiet riding experience. Its innovative torque sensor can adapt to a highly flexible riding curve for different biking scenarios. Its algorithm allows high-precision delay and inertia compensation for a smoother and more stable riding experience.
Welling W8500 for mountain E-bikes: Its unique flat wire winding structure with optimized design can enable efficiency to reach 80%, and increase battery range in mountain biking. Its ultra-high overload capacity can run continuously at 75% peak torque while keeping the shell temperature below 60°C for longer service life and more powerful output. Its highly integrated design enables it to have a weight of less than 3 kg in a very compact size.
Motinova MT6000: This high-performing central motor for large chain wheels is designed for urban commuters. The motor is only 3 kg and is very delicate. It could provide a maximum assistance rate of 270% in a strong and quiet momentum. Its pedaling rate can reach as high as 100rpm with five riding modes. Bikers can enjoy the fun of riding in all kinds of road conditions.
Motinova motors for small chain wheels, such as the VOLANS and PEGASI series; cycle computers; accessories; and other biking offerings are also on exhibition. In the outdoor exhibition area, Motinova and Welling also provide a fun test riding experience, “Ride Longer, Live Better.”
Motinova and Welling will further enhance their core capabilities in the field of intelligent transportation and the two-wheel transportation market.
Motinova’s and Welling’s parent, Midea Industrial Technology, has built 27 R&D centers in China, Austria, India, and Japan, with an accumulation of more than 5,500 authorized patents.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005981/en/
Contact information
Zhang Haichun
zhanghc69@midea.com
+86-18600038145
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom